CAS: 918633-87-1; 2-Bromo-N-[(2-Bromoethylamino)-[(3-Methyl-2-Nitroimidazol-4-yl)Methoxy]Phosphoryl]Ethanamine

该化合物是细胞毒性电离层剂溴-异磷磷胺芥子体的缺氧活性助药,旨在有选择地瞄准并释放其在缺氧条件下的活性运动,这是许多固态肿瘤的标志.这种激活机制在提高缺氧地区抗菌药效的同时,最大限度地减少了系统毒性,而缺氧地区往往抗常规疗法. Evofosfamide在治疗各种癌症,包括泛丙胺,软组织沙马和凝固粘土瘤的临床前期和临床研究中表现出潜力. 它与放射疗法和其他乳液化剂的同步能力进一步凸显了其在组合疗法中的效用. 化合物的缺氧选择性激活为克服肿瘤与微观环境有关的治疗抗药性提供了很有希望的方法.

结构式图片

上下游产品

(3-甲基-2-硝基-3H-咪唑-4-基)-甲醇 (1-Methyl-2-Nitro-1H-Imidazol-5-yl)Methanol 39070-14-9
3-甲基-2-硝基-3H-咪唑-4-甲酸乙酯 Ethyl 1-Methyl-2-Nitro-1H-Imidazole-5-Carboxylate 39070-13-8

合成工艺路线路线简述

  • 2057422-26-9 + 39070-14-9 = 918633-87-1
    反应条件:1.1 Reagents: Triethylamine Solvents: Dichloromethane; Overnight,0 °C
    标题:Synthesis And Evaluation Of Radiolabeled Phosphoramide Mustard With Selectivity For Hypoxic Cancer Cells
    作者:Zhang,Wenting; Fan,Wei; Zhou,Zhengyuan; Garrison,Jered
    参考文献:Acs Medicinal Chemistry Letters 日期:2017 卷标:8(12) 页码:1269-1274]

    141025-16-3 + 39070-14-9 = 918633-87-1
    反应条件:1.1 Reagents: Triphenylphosphine,Diisopropyl Azodicarboxylate Solvents: Tetrahydrofuran; 0 °C -> Rt; Overnight,Rt
    标题:Synthesis And Biological Evaluation Of Hypoxia-Activated Prodrugs Of Sn-38
    作者:Jin,Chen; Zhang,Qiumeng; Lu,Wei
    参考文献:European Journal Of Medicinal Chemistry 日期:2017 卷标:132 页码:135-141]

    141025-16-3 + 39070-14-9 = 918633-87-1
    反应条件:1.1 Reagents: Triphenylphosphine,Diisopropyl Azodicarboxylate Solvents: Tetrahydrofuran; 0 °C -> Rt; 2 H,Rt
    标题:Potent And Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards As Anticancer Drugs
    作者:Duan,Jian-Xin; Jiao,Hailong; Kaizerman,Jacob; Stanton,Timothy; Evans,James W.; Et Al
    参考文献:Journal Of Medicinal Chemistry 日期:2008 卷标:51(8) 页码:2412-2420]

    2576-47-8 + 39070-14-9 = 918633-87-1
    反应条件:1.1 Reagents: Triethylamine,Phosphorus Oxychloride Solvents: Dichloromethane; 1 H,-30 °C1.2 Reagents: Triethylamine; 2 H,Rt1.3 Reagents: Hydrochloric Acid Solvents: Water; Ph 7,Rt
    标题:Method For Preparing Evofosfamide
    参考文献:China
📜3-甲基-2-硝基-3H-咪唑-4-甲酸乙酯置于偶氮二甲酸二异丙酯,水,三乙胺,三苯基膦,Sodium Hydroxide体系中,用 四氢呋喃 作为反应溶剂,化学反应 2.0H,反应生成 Th 302; N,N'-双(2-溴乙基)二氨基膦酸 (1-甲基-2-硝基-1H-咪唑-5-基)甲酯
参考文献: Th-302 Solid Forms And Methods Related Thereto[fr] Formes Solides De Th-302 Et Procédés Associés
标题: Th-302 Solid Forms And Methods Related Thereto[fr] Formes Solides De Th-302 Et Procédés Associés
摘要:本发明提供了一种制备th-302及其固态形式的新方法.该化合物的固态形式是一种有效的抗癌剂,并可用于各种制药组合物中,特别适用于治疗癌症.本发明还提供了一种制备这种化合物和形式以及治疗哺乳动物癌症的方法,包括给予治疗有效量的th-302固态形式.

海关参考信息

专利信息


专利号:US-2025011348-A1
优先权日:2023-06-13
标题:Synthesis Process of X-IPM, Stable Crystal Form and Application Thereof
发明人:DUAN JIANXIN; LU ZHAOQIANG; CAI XIAOHONG; FAN JINWEI; QIN WEI; HUANG QUNHUI; ZHANG YANJUN; CHEN WEISU
权利人:ASCENTAWITS PHARMACEUTICALS LTD
摘要:The present application relates to a new method for synthesizing isophosphoramide nitrogen mustard (X-IPM) that is suitable for industrialized production, involves fewer types of solvents, and leads to stable products with high yield. This method is charazterized mainly by the batchwise addition of M (e.g., M is R3N with R being ethyl; i.e., M is triethylamine) and the specific post-reaction treatment, which make it possible for the reaction to fully proceed, lead to products with less impurities, high yield and relatively stable properties, and can lead to stable crystallized substances with specific crystal structures. The present application also relates to stable crystal forms of the isophosphoramide nitrogen mustard (X-IPM) prepared by the aforementioned method, and use of the same as reactants for the synthesis of aziridine structure-containing compounds.

专利号:US-2016251387-A1
优先权日:2013-10-10
标 题:Synthesis of 1-alkyl-2-amino-imidazol-5-carboxylic acid ester via calpha-substituted n-alkyl-glycine ester derivatives
发明人:JASPER CHRISTIAN; HAHN HELMUT DIETER; BREUNING MARCEL ANDRE; KRATTIGER PHILIPP; DEBOR MICHAELA
权利人:MERCK PATENT GMBH
摘要:The invention provides an efficient and high yielding process for preparing TH-302, comprising at least one step wherein a dioxolane intermediate is generated in an aqueous layer, resulting in a synthesis that is amenable to scale up conditions.

专利号:US-2024425461-A1
优先权日:2023-06-13
标题 :Preparation process of intermediate, synthesis process of amino imidazole carboxylate ester and hplc purity measure method
发明人:DUAN JIANXIN; LU ZHAOQIANG; FAN JINWEI; HUANG QUNHUI; ZHANG YANJUN; CHEN WEISU; QIN WEI
权利人:ASCENTAWITS PHARMACEUTICALS LTD
摘要:This invention relates to a process for preparing an intermediate of aminoimidazole carboxylate, a process for synthesizing aminoimidazole carboxylate and an HPLC method for determining purity. The process of preparing the intermediate of aminoimidazole carboxylate comprises subjecting a compound of formula I-2 and a formate as the reactants to a first-step reaction in a benzene solvent and at a temperature of −5° C.−5° C., with the addition of a solution of sodium alkoxide in such a way that the temperature of the reaction solution is not higher than 5° C., to obtain the intermediate of aminoimidazole carboxylate or a mixture comprising a compound of formula I-3, i.e., the intermediate of aminoimidazole carboxylate. By using a sodium alkoxide reagent, as a comparatively safe alternative to NaH and potassium tert-butoxide which are prone to cause fire hazards or explosions and are not suitable for use in large-scale production, the process of the present application can ensure smooth progression of the reaction to the product and effectively improve the overall safety of the reaction without noticeably impairing the reaction efficiency.

专利号:US-2024208898-A1
优先权日:2021-03-25
标 题 :Enamine n-oxides: synthesis and application to hypoxia-responsive prodrugs and imaging agents
发明人:KIM JUSTIN; KANG DAHYE; CHEUNG SHELDON T
权利人:DANA FARBER CANCER INST INC
摘要:Disclosed are compounds and pharmaceutically acceptable salts and stereoisomers thereof that are suitable for diagnosis and the treatment of diseases and disorders characterized by, associate with or which exhibit tissue hypoxia, such as, for example, solid tumors. Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds.

专利号:WO-2015051921-A1
优先权日:2013-10-10
标题:Synthesis of 1-alkyl-2-amino-imidazol-5-carboxylic acid ester via calpha-substituted n-alkyl-glycine ester derivatives

专利号:CN-116789558-A
优先权日:2022-03-18
标题:Preparation method of intermediate, synthesis method of amino imidazole carboxylate and HPLC (high performance liquid chromatography) purity detection method

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Pourmorteza M, Rahman ZU, Young M. Evofosfamide, a new horizon in the treatment of pancreatic cancer. Anticancer Drugs. 2016 Sep;27(8):723-5. doi: 10.1097/CAD.0000000000000386. 8(1):53. doi: 10.1186/s13550-018-0409-1.
3: Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, Chiorean EG, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, Lee TW, Grénman RA, Caporiccio L, McKee TD, Zaidi M, Butt S, Macann AM, McIvor NP, Chaplin JM, Hicks KO, Bohlander SK, Wouters BG, Hart CP, Print CG, Wilson WR, Curran MA, Hunter FW. Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. JCI Insight. 2018 Aug 23;3(16):e122204. doi: 10.1172/jci.insight.122204. Erratum in: JCI Insight. 2023 Feb 22;8(4):
4: Kishimoto S, Brender JR, Chandramouli GVR, Saida Y, Yamamoto K, Mitchell JB, Krishna MC. Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy. Antioxid Redox Signal. 2021 Oct 10;35(11):904-915. doi: 10.1089/ars.2020.8131. Epub 2020 Sep 15.

合成参考文献


参考文献:10.1038/s41575-018-0005-x
摘要:Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nature Reviews Gastroenterology & Hepatology. 2018 May 01;15(6):333–48. doi: 10.1038/s41575-018-0005-x.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知